Research Article

Gpx3 and Egr1 Are Involved in Regulating the Differentiation Fate of Cardiac Fibroblasts under Pressure Overload

Guoxing Li,1 Yuhong Qin,2 Zhe Cheng,3 Xiaocheng Cheng,1 Ruiyu Wang,1 Xuexiu Luo,4 Yipin Zhao,5 Dongying Zhang6,1 and Gang Li6,7

1Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
2Department of Hepatology and Translational Medicine, Chongqing University Fuling Hospital, Chongqing 400016, China
3Department of Cardiology, Chongqing University Three Gorges Hospital, Chongqing 404199, China
4Department of Critical Medicine, Fuqing Hospital Affiliated to Fujian Medical University, Fuqing 350300, China
5Department of Cardiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
6Institute of Life Sciences, Chongqing Medical University, 400016, China
7Molecular Medicine Diagnostic and Testing Center, Chongqing Medical University, 400016, China

Correspondence should be addressed to Dongying Zhang; zhangdongying@cqmu.edu.cn and Gang Li; ligang@cqmu.edu.cn

Received 13 March 2022; Revised 21 May 2022; Accepted 3 June 2022; Published 28 June 2022

Academic Editor: Tao Li

Copyright © 2022 Guoxing Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. Although myocardial fibrosis is a common pathophysiological process associated with many heart diseases, the molecular mechanisms regulating the development of fibrosis have not been fully determined. Recently, single cell RNA sequencing (scRNA-seq) analysis has been used to examine cellular fate and function during cellular differentiation and has contributed to elucidating the mechanisms of various diseases. The main purpose of this study was to characterize the fate of cardiac fibroblasts (CFs) and the dynamic gene expression patterns in a model of cardiac pressure overload using scRNA-seq analysis. Methods. The public scRNA-seq dataset of the transverse aortic coarctation (TAC) model in mice was downloaded from the GEO database, GSE155882. First, we performed quality control, dimensionality reduction, clustering, and annotation of the data through the Seurat R package (v4.0.5). Then, we constructed the pseudotime trajectory of cell development and identified key regulatory genes using the Monocle R package (v2.22.0). Different cell fates and groups were fully characterized by Gene Set Enrichment Analysis (GSEA) analysis and Transcription factor (TF) activity analysis. Finally, we used Cytoscape (3.9.1) to extensively examine the gene regulatory network related to cell fate. Results. Pseudotime analysis showed that CFs differentiated into two distinct cell fates, one of which produced activated myofibroblasts, and the other which produced protective cells that were associated with reduced fibrosis levels, increased antioxidative stress responses, and the ability to promote angiogenesis. In the TAC model, activated CFs were significantly upregulated, while protective cells were downregulated. Treatment with the bromodomain inhibitor JQ1 reversed this change and improved fibrosis. Analysis of dynamic gene expression revealed that Gpx3 was significantly upregulated during cell differentiation into protective cells. Gpx3 expression was affected by JQ1 treatment. Furthermore, Gpx3 expression levels were negatively correlated with the different levels of fibrosis observed in the various treatment groups. Finally, we found that transcription factors Jun, Fos, Atf3, and Egr1 were upregulated in protective cells, especially Egr1 was predicted to be involved in the regulation of genes related to antioxidant stress and angiogenesis, suggesting a role in promoting differentiation into this cell phenotype. Conclusions. The scRNA-seq analysis was used to characterize the dynamic changes associated with fibroblast differentiation and identified Gpx3 as a factor that might be involved in the regulation of myocardial fibrosis under cardiac pressure overload. These findings will help to further understanding of the mechanism of fibrosis and provide potential intervention targets.
1. Introduction

The heart compensates for increased workload through structural remodeling, which can ultimately lead to heart failure [1]. Myocardial fibrosis, as a form of cardiac remodeling, is a common process in many pathophysiological states, such as hypertension [2], myocardial infarction [3], and valvular disease [4]. In response to injury, myocardial fibroblasts show abnormal activation and secrete excessive extracellular matrix, resulting in chamber wall stiffness and diastolic dysfunction [5]. Many studies have revealed potential mechanisms associated with myocardial fibrosis. Myocardial fibrosis is the result of crosstalk between various types of cells, such as macrophages, which can secrete pro- and anti-fibrotic factors [6], regulatory T cells, which can participate in regulating fibrosis by inhibiting excessive inflammation [7], and endothelial cells, which can secrete factors that interfere with the process of fibrosis [8]. Moreover, inflammatory reactions [9], oxidative stress [10], energy metabolism [11], apoptosis [12], and other mechanisms all play a role in the regulation of fibrosis. However, despite recent scientific advances, the current anti-fibrotic treatment options are still limited [13]. Therefore, exploring the mechanism of myocardial fibrosis and developing new therapeutic interventions are critical.

In recent years, single cell RNA sequencing (scRNA-seq) has become a standard tool for medical research that has been used in many fields [14]. Single cell sequencing allows for analysis of cell heterogeneity, intercellular communication, and cell developmental trajectories, which are important in the study of tissue development and pathology [15]. Several therapeutic targets for myocardial fibrosis, such as Ddah1, Meox1, and Citrck1, have been identified by single cell sequencing analysis and have provided novel theoretical targets for the treatment of myocardial fibrosis [16–18].

The purpose of this study was to explore the heterogeneity and activation of myocardial fibroblasts in a stress overload mouse model using scRNA-seq analysis. Our aim was to clarify some of the mechanisms of fibrosis and explore potential targets for treating myocardial fibrosis.

2. Materials and Methods

2.1. Analysis and Integration of scRNA-seq Data. The data sets analyzed in this study were obtained from the GEO database (https://www.ncbi.nlm.nih.gov/geo/). First, we filtered the presumed doublet cells through DoubletFinder (v2.0.3) [19]. R package Seurat (v4.0.5) [20] was used for data integration, cell filtration, normalization, clustering, and UMAP or tSNE dimensional reduction. Harmony (v0.1.0) [21] was used to remove the batch effect between groups. Overall, we excluded cells with nFeatures < 200, nFeatures > 3,000, and percent.mt > 10% for initial quality control. After clustering, the cells with the most significant differences in nFeatures and percent.mt were further excluded.

2.2. Pseudotime Trajectory Analysis. Monocle2 was used for pseudotime analysis [22]. Cell progression genes were defined based on differential gene expression between Seurat clusters. "BEAM_res" function was used for analysis of gene dynamics during cell differentiation.

2.3. Gene Ontology (GO) Enrichment Analysis. Enriched GO terms in differentially expressed genes were identified using the clusterprofileR package (v0.5.0) [23] with the default parameters.

2.4. Hub Gene Analysis. First, differential genes were introduced into the STRING v11 database (https://string-db.org/) to obtain the PPI network. Then, hub genes were analyzed via Cytoscape v3.9.1 [24]. Notably, the hub genes were ranked by "degree."

2.5. Gene Set Enrichment Analysis (GSEA). The GSEABase (v1.56.0) package (http://www.bioconductor.org/packages/release/bioc/html/GSEABase.html) was used to complete GO and KEGG enrichment analysis of marker genes in all groups.

2.6. Transcription Factor Activity Evaluation and Transcription Factor Target Overrepresentation Analysis. The transcription factor activity of different cell states was predicted using the DoRothEA (v1.6.0) package [25] with default parameters. The transcription factors of gene sets related to angiogenesis and antioxidant stress were predicted by ChEA3 [26], and the gene sets were submitted online (https://maayanlab.cloud/chea3/). By comparing multiple libraries and scoring, the top 15 transcription factors were finally obtained by sorting with “mean rank.”

2.7. Receptor Ligand Interaction Analysis. We evaluated intercellular receptor ligand signals with NichNet [27], fibroblasts were used as sender and endothelial cells as receiver, and the other parameters were default.

3. Results and Discussion

3.1. The scRNA-seq Analysis of Cardiac Fibroblasts (CFs) in a Transverse Aortic Coarctation (TAC) Model. Alexian et al. [17] established TAC and Sham models in mice and administered JQ1 [28], a small molecule BET bromodomain inhibitor, 18 days later. Mice were treated with JQ1 for one month, then JQ1 treatment was stopped in one cohort of mice for 14 days. Finally, the heart samples (n = 2) of four groups were harvested for single cell sequencing (Figure 1(a)). First, we carried out quality control on the data and identified a total of 58,175 cells; after quality control, the data had no significant batch effect, and the nFeatures and percen.mt of the data were within a reasonable range (Supplementary Figure 1(a, b)). After dimensionality reduction and clustering, these cells were annotated according to marker genes (Supplementary Table 1). A total of 14 cell subtypes were obtained (Figure 1(b)), in which activated CFs expressed high levels of profibrotic factors such as Postn, Sparc, and Cilp [29–31]. Ly6a+ CFs expressed high levels of the stem cell marker Ly6a [32] and fibrotic inhibitor Pit16 [33]. Another group of CFs (G0s2+ CFs) showed high expression of G0s2, which blocks lipolysis and inhibits the cell cycle [34], as well as...
Figure 1: Continued.
Figure 1: Continued.
expressing the Antioxidant stress-related gene Gpx3 [35] and cardioprotective gene Adm [36] (Supplementary Figure 1(c)).

To further explore CF heterogeneity in cardiac fibrosis, we defined additional CF populations using unsupervised graph-based clustering and UMAP. In total, nine cell clusters were identified in the whole dataset (Figure 1(c)). We extracted the top marker genes with the largest standard deviation of each cell cluster to calculate the correlation.
Figure 2: Continued.
Oxidative phosphorylation
Supramolecular fiber organization
Atp metabolic process
Tissue remodeling
Negative regulation of response to oxidative stress
Myeloid leukocyte activation
Cell-cell adhesion

GSEA of GO
Oxidative phosphorylation

GSEA of KEGG
Drug metabolism cytochrome p450
Regulation of actin cytoskeleton
Fatty acid metabolism

TAC+JQ1 withdrawn
Sham
TAC

(f)

TF activity

Lhx2
Smad3
Epsa1
Crem
Rumx2
Ate6
Tead1
Atf7
Nr4a1
Arntl
Myc
Twist1
Thap11
Hnf4a
Rest
Elk1
Sox13
Ets2
Nkx11
Foxo3
Ate2
Foxd2
Stat6
Ahr
Esr2

(g)

Figure 2: Continued.
Based on this, we reclassified these nine cell clusters into five CF subgroups, C1-C5 (Figure 1(d)). C1 and C4 displayed high expression levels of profibrotic genes such as Postn, Ctgf, and Meox1, indicating that these cell groups had a stronger fibrotic phenotype. C2 overexpressed Apeo, G0s2, and Lpl, which are thought to be related to fat metabolism, while C3 overexpressed Ly6a, Pi16, and Cd248. Gene expression levels in the C4 and C5 subgroups were not as high as those observed in the C1-C3 subgroups and were therefore considered to be cell subsets in a transition state (Figures 1(e) and 1(g)). Although we did not observe significant batch effects, there were significant differences in cell distribution among the different groups (Figure 1(f)). As shown in Figure 1(h), the number of cells in C1 and C4 was significantly increased in the TAC group, decreased after treatment with JQ1, and partially attenuated by JQ1 withdrawal. Since changes in the number of cells in the C2, C3, and C5 subgroups were the opposite of those found in C1 and C4, we concluded that these two types of cells played different roles in CFs under pressure overload.

3.2. JQ1 Treatment Attenuates Oxidative Stress and Fibrosis in CFs. Since JQ1 can improve fibrosis and enhance cardiac function, examining the characteristics of the four treatment groups may further our understanding of the mechanisms of fibrosis. We analyzed the marker genes of each group and displayed the data by volcano plot. The TAC group showed high expression of profibrotic-related genes such as Ctgf, Cilp, and Thbs1, as well as high expression of Actn1 and Crsp2, which are associated with actin contraction (Figure 2(b)). After JQ1 treatment, the fibrotic-related genes were significantly downregulated, while upregulation of the heart protective genes Eef2 [37] and Dusp1 [38] was observed (Figure 2(c)). To some extent, JQ1 treatment restored the gene expression pattern in the TAC group to that observed in the Sham group (Figure 2(a)). Withdrawal of JQ1 resulted in downregulation of the protective and fibrogenic genes, which might explain lower levels of heart protection in the JQ1 withdrawal group compared to the JQ1 treatment group (Figure 2(d)). Next, we obtained the marker genes of each group with the parameters of "min.pct = 0.01, logfc.threshold = 0" and sorted them by "log2FC." Then, we performed GO and KEGG enrichment analysis of the marker genes for each group and displayed them with radar plot (Supplementary Table 2). GO terms related to fibrosis, such as "Supramolecular Fiber Organization" and "Cell Cell Adhesion," were significantly upregulated in the TAC group, but improved after JQ1 treatment. In addition,
we found that JQ1 significantly improved oxidative stress, and no significant differences in the enrichment level of the GO term “Negative Regulation Of Response To Oxidative Stress” were observed between the TAC + JQ1 and Sham groups (Figure 2(e)). Similar results were found by KEGG enrichment analysis. For example, the gene set “Drug Metabolism Cytochrome P450” related to antioxidative stress and including genes such as Gstm1, Gsta3, and Gpx3 was found to be upregulated in the JQ1 treatment group compared to the TAC group.

Next, we studied the effect of JQ1 therapy on fibrosis. We obtained a gene list of fibrosis-related GO terms (Supplementary Table 3) and used heat map to compare their expression in the four groups. We found that fibrosis-related genes in the TAC group were significantly upregulated compared to those in the Sham group, and that JQ1 treatment reversed this outcome, while withdrawal of JQ1 weakened the JQ1-induced improvement in fibrosis (Figure 2(f)). The expression of representative fibrogenic genes is shown in Figure 2(h) and is consistent with the heat map data. Because transcription factors regulate gene expression, they play an important role in the development of diseases. Thus, we analyzed the activity of transcription factors in each group. Our data revealed significant upregulation of Atf6, Runx2, Crem, and Tead1 in the TAC group, with Atf6 and Runx2 associated with oxidative stress [39, 40], while Crem and Tead1 were involved in promoting fibrosis [41, 42]. Transcription factor activity levels in the TAC + JQ1 and Sham groups were very similar, with Atf2, Elk1, Ets1, and Esr1 associated with inhibition of oxidative stress [43–45]. In the TAC + JQ1 withdrawal group, both protective and harmful transcription factor activities were impaired (Figure 2(g)).

3.3. Differential Fates of CF Differentiation. Our data indicated that the four CF treatment groups had different fibrotic phenotypes and biological functions. Next, we examined the differentiation trajectories of CFs and compared the differences between the groups through pseudotime analysis. In the cell trajectory, we identified three main branches, which we named branches 1 – 3 (Figure 3(c)). As a putative starting point of development, branch 1 was mainly composed of C4, which highly expressed the stem cell marker, Ly6a. Two distinct differentiation fates were derived from branch 2. Branch 2 was mainly composed of C2 and C5, while branch 3 was mainly composed of C1 and C4, which exhibited high expression levels of fibrogenic genes (Figures 3(a) and 3(b)). We evaluated the proportion of branches in each group and found that the TAC group was dominated by branch 3, suggesting that branch 3 was closely related to the fibrotic phenotype. In contrast, the JQ1 treatment group showed a significant reduction in the proportion of branch 3, even larger than that observed in the Sham group (Figure 3(c)). A higher proportion of branch 2 was observed in the JQ1 treatment group relative to the Sham group, suggesting that JQ1 treatment altered the fate of CFs.

To explore the mechanism of CF differentiation, we evaluated the gene dynamics of two different cell fates. Genes were divided into three clusters according to their expression patterns: genes of cluster 2 were gradually upregulated in branch 2, while genes of cluster 1 and cluster 3 were gradually upregulated in branch 3 (Figure 3(e)). Genes of cluster 2 were found to be mainly enriched in angiogenesis and ribosome composition (Supplementary Table 4). We further analyzed its PPI network using Cytoscape and sorting genes by “Eccentricity.” Of the selected top 20 genes, Gstt1, Gpx3, Gstm1, Gpc3, and Ggt5 were widely considered to be related to antioxidative stress. The gene function of cluster 3 was mainly enriched in actin filament organization, and its top 20 genes (sorted by degree) included Actb, Actg1, and Actr3. The top 20 genes (sorted by degree) of cluster 1 included Acta2, Tgb1, Postn, Ctgf, and Colla1, which are well-established fibrogenic genes. The GO enrichment analysis data were consistent with these findings. The expression of genes related to fibrosis and oxidative stress in each branch was evaluated by violin plot. We found that branch 2 had reduced expression of fibrosis-related genes and increased expression of genes associated with antioxidative stress (Figures 3(f) and 3(g)).

3.4. Gpx3 May Be Involved in Regulating the Differentiation of CFs. According to the results described above, genes of cluster2 that were upregulated in branch 2 were associated with angiogenesis and antioxidative stress. In order to further explore its specific mechanism, we selected the top 100 genes in the PPI network of cluster 2 and classified each gene according to reports in the literature (Figure 4(a)). Genes labelled blue are related to ribosomal synthesis, while yellow-labelled genes may be involved in the negative regulation of fibrosis. The dark-green-labelled genes encode transcription factors that play a protective role in a variety of diseases. In addition, gene sets labelled red such as Gpx3, Ggt5, and Gstm1 were considered to be associated with antioxidative stress, and the differential expression of these genes in the cell trajectories was evaluated further. The expression of Gpx3, Gstm1, Ggt5, and Gsta3 showed different trends in the two cell fates, in contrast to Postn, Sparc, and Ctgf expressions (Figure 4(b)). Compared with other red-labelled genes, the expression of Gpx3 in the cell track changed more significantly (Supplementary Figure 2(a)) and compared its expression pattern with Postn and Colla1. Gpx3 was mainly expressed in branch 2, while Postn and Colla1 were predominantly expressed in branch 3. Furthermore, Gpx3 was downregulated in the TAC group and upregulated after treatment with JQ1, whereas withdrawal of JQ1 weakened the JQ1-induced upregulation of Gpx3. Meanwhile, the expression trend of the profibrotic gene Postn and Colla1 was the opposite of Gpx3 (Supplementary Figure 2(b)). These data suggested that Gpx3 may inhibit CFs from differentiating into branch 3 and may promote differentiation into branch 2. In addition, we found that Apoe, Lpl, and Socs3 were also highly expressed in branch 2, suggesting that there might be metabolic differences between the branches. Thus, we evaluated the expression of metabolism-related genes in each group and found that the fatty acid metabolism levels of branch 2 were significantly increased, while the glycolysis and mitochondrial respiration levels were decreased,
Figure 3: Simulation of the developmental trajectory of CFs and analysis of gene expression patterns inferred by Monocle2. (a) Pseudotime trajectory analysis of fibroblasts, using significantly regulated genes between C1 and C5. The color gradient indicates pseudotime progression. (b) Cell trajectories were renamed according to three main branches. (c) GO biological process terms enriched in each gene cluster. (f) Heat map hierarchical clustering showing differentially expressed genes together with the pseudotime curve. Color key from green to purple indicates relative expression levels from low to high. (g) Gene network displaying the top 20 hub genes from each cluster. (h, i) Expression of representative pro-fibrotic genes and antioxidative stress genes in each branch.
Figure 4: Continued.
3.5. CFs of Branch 2 Are Involved in Promoting Angiogenesis.

It is interesting to note that, as shown in Figure 3(e), genes that were gradually upregulated in branch 2 were mainly associated with angiogenesis. Because CFs are unable to promote the sprouting of endothelial cells directly, we assumed that CFs promote angiogenesis by secreting proteins. Thus, we downloaded 3970 genes encoding secretory proteins (Supplementary Table 5), as well as angiogenesis-promoting genes (Supplementary Table 6), and intersected them with the marker genes of each branch. We found that four marker genes in branch 1 encoded angiogenic secretory proteins, compared to five in branch 3, and 12 in branch 2 (Figures 5(a)–5(c)). Figure 5(d) shows the expression of these 12 genes through violin plot. Our data indicated that branch 2 had the largest number of genes encoding proteins that promote angiogenesis compared with the other two branches, which was consistent with the results described above. Next, we selected CFs and endothelial cell subsets and mapped the branch labels of the trajectory of CFs into these cells (Supplementary Figure 3(b)). Then, the NicheNet package was used to explore the ligand-receptor (L-R) signal communication between the three branches of CFs and endothelial cells. Trf and Lamb1 were found to be highly expressed in branch 2, while Manf and Bdnf were highly expressed in branch 3. Based on the L-R pairs shown in Figure 5(g), we identified the corresponding receptors. Itga6 was identified as the receptor of Lamb1 and was found to be highly expressed in capillary endothelial cells, while Fzd4 was the receptor of Trf, which was shown to be enriched in arterial endothelial cells. Both receptors have been shown to be associated with angiogenesis. F11r, the receptor of Bdnf, was expressed in arterial endothelial cells and has been reported to be associated with atherosclerosis. Sec63 was found to be the receptor of Manf and was widely expressed in CFs of branch 3.

3.6. Egr1 May Be Involved in Reprogramming the Fate of CFs.

In the gene network of branch 2, multiple genes encoding transcription factors were upregulated and served as the core of the network (Figure 4(a)). Transcription factors play an important role in the pathophysiological process of disease, and thus, in-depth examination of these transcription factors will improve our understanding of fibroblast differentiation. With the exception of Atf3 and Fosb, these transcription factors were widely expressed in CFs and were significantly upregulated in branch 2 (Figure 6(a)). The expression levels of these transcription factors were found to be decreased in the TAC group, but increased after JQ1 treatment, and decreased after JQ1 withdrawal. These findings were consistent with the Gpx3 data, but in contrast to the Postn data (Figure 6(b)). Similarly, the changing trends of these transcription factors on cell trajectories were consistent with Gpx3 but opposite to Postn (Figure 6(c)). Since the expression levels of these transcription factors were consistent with those of Gpx3, Postn, and genes encoding angiogenesis-promoting secretory proteins, we further predicted the transcription factors of these genes by ChEA3. Egr1 was identified from the top 15 predicted transcription factors and was also found to be highly expressed in branch 2. Based on the above results, we speculated that Egr1 may especially mitochondrial respiration. Of note, branch 3 had the highest glycolysis level among all branches (Figure 4(c)). We also evaluated the levels of pentose phosphate pathway, glycogen synthesis, glycogen decomposition, and gluconeogenesis, and the results showed no significant difference (Supplementary Figure 3(a)).

Figure 4: Examination of the function of upregulated genes in branch 2. (a) The top 100 hub gene network in gene cluster1 (described in Figure 2(f)), showing genes that were upregulated in branch 2. The function of these genes was classified and color-coded based on reports in the literature. (b) Differences in expression of Gpx3, Gstm1, Gsta3, Ggt5, and fibroblast-promoting genes in the different cell trajectories. (c) Heat map showing the relative expression levels of key genes related to fatty acid (FA) signals, tricarboxylic acid (TCA) cycle, glycolytic pathway, and mitochondrial respiration in each branch.
Markers of branch 1

Markers of branch 2

Markers of branch 3

Figure 5: Continued.
Figure 5: Continued.
be an upstream transcription factor that has a role in improving oxidative stress and promoting angiogenesis.

4. Discussion

This study fully characterized the heterogeneity of CFs in a mouse TAC model, as well as the cell development trajectory through scRNA-seq analysis. Based on scRNA-seq analysis, we propose for the first time that there are two distinct cell differentiation fates for CFs under pressure overload. Fibroblasts expressing the stem cell marker Ly6a served as the starting point of differentiation (branch 1), from which two types of cell differentiation trajectories were derived, one of which was involved in the promotion of fibrosis (branch 3) and the other, which was involved in antioxidative stress and angiogenesis (branch 2). In the nonstress state, CFs are mainly differentiated into branch 2. However, under pressure overload conditions, CFs increased their differentiation into branch 3, which promoted fibrosis. Treatment with JQ1 significantly restored the fate of branch 2 and significantly alleviated fibrosis levels, which proved to be the powerful therapeutic effect of JQ1.

GSEA analysis revealed that the PPAR signaling pathway in the TAC heart was significantly downregulated compared with the Sham group. PPARs belong to the nuclear hormone receptor superfamily [46, 47]. PPARy expression is closely associated with myocardial fibrosis [48, 49], due to its involvement in regulating inflammation, energy metabolism, and oxidative stress [50–53]. PPAR agonists are expected to be beneficial in antmyocardial fibrosis therapy [54]. Furthermore, CFs in branch 2 were found to express high levels of Apoe, Lpl, and Socs3, which are related to lipid metabolism. To evaluate metabolic differences in fibroblast differentiation, we evaluated the expression of key genes of fatty acid metabolism, glycolysis, the TCA cycle, and mitochondrial respiratory chain in cell development trajectories. We found that during the differentiation of fibroblasts into nonprotection branch 3, glycolysis levels gradually increased and were accompanied by a reduction in fatty acid metabolism. Thus, the balance of normal cardiac energy substrates was dysregulated, and so, under pressure overload, fibroblasts tend to be fueled by the glycolytic pathway. Many studies have reported that excessive glycolysis is involved in the process of organ fibrosis. Thus, inhibition of glycolysis can inhibit the activation of fibroblasts and improve organ fibrosis [55–58]. This change of energy metabolism may be an adaptive measure under hypoxia, as cells tend to undergo glycolysis in the absence of oxygen [59, 60]. Thus, we speculate that restoring normal levels of fatty acid metabolism may be a potential treatment for fibrosis.

Next, we assessed the level of oxidative stress in fibroblasts in each group. We found that the ability to resist oxidative stress was significantly impaired in the TAC group. Oxidative stress also plays an important role in the differentiation of fibroblasts. CFs that differentiated into branch 2 exhibited higher antioxidative stress abilities. However, differentiation into branch 3 was accompanied by a reduction in antioxidative stress ability. JQ1 treatment promoted the differentiation of cells into branch 2 and significantly restored the expression levels of antioxidative stress-related genes in fibroblasts, especially Gpx3. However, the withdrawal of JQ1 partially weakened this protective effect. These results indicated that oxidative stress was involved in the regulation of fibrosis, while JQ1 was found to have an anti-fibrotic role, at least in part through the regulation of oxidative stress [61–64]. Notably, Sdhb and Sdha, key genes involved in mediating succinic acid metabolism, were significantly reduced in fibroblasts from the TAC heart. However, previous studies have reported that Sdh-mediated succinic acid oxidation drives mitochondria to produce ROS, which is involved in the promotion of oxidative stress injury [65, 66]. This may be the compensation mechanism of energy metabolism reprogramming to cope with oxidative stress [67–70].

**Figure 5:** CFs participate in angiogenesis. (a)–(c) The secretory protein gene set and the angiogenic gene set were, respectively, intersected with the marker genes of each branch. Four overlapping genes were found in branch 1, 12 in branch 2, and five in branch 3. (d) Vennplot showing the expression of 12 genes encoding angiogenesis-promoting secretory proteins in branch 2. (e) Top ligands in each cell type obtained by NicheNet analysis. (f) Top receptors in each cell type. (g) L-R pairs between cell types.
Figure 6: Continued.
In addition, we observed an interesting phenotype. We found that, compared with other branches, branch 2 had a higher ability to promote angiogenesis, due to increased production of secreted proteins that promote angiogenesis, such as C3, Mdk, Pgf, and Ramp2 [71–73]. We analyzed the L-R signals between CFs of the three branches and endothelial cells via NicheNet and obtained similar results. We identified Trf-Fzd4 and Lamb1-Itga6 as the L-R pairs between branch 2 and ECs. Studies have shown that Fzd4, as a receptor of Wnt, participates in promoting angiogenesis [73], while Itga6 promotes endothelial morphogenesis through regulation of Cxcr4 [74]. Bdnf-F11r was identified as a L-R pairs.
pair between branch 3 and endothelial cells. A role for F11r in promoting atherosclerosis has previously been reported [75]. Our results indicated that branch 2, as one of the potential fates of fibroblast differentiation, has an increased ability to promote angiogenesis. The concept of fibroblasts having a role in the promotion of angiogenesis is not new. Fibroblasts reportedly exhibit characteristics associated with promoting angiogenesis on the third day after myocardial infarction but have an antiangiogenesis role on day 7 [76]. This mechanism also plays an important role in tumor angiogenesis [77]. Our results not only support this concept but also clearly show that CFs that promote angiogenesis constitute one of the branches of CF fate. At the same time, this branch has a strong antioxidative stress capability, as well as increased fatty acid metabolism.

Finally, we evaluated the expression of transcription factors such as Jund, Fos, Atf3, and Egr1 in branch 2. Expression of these transcription factors was reduced in the TAC group, but improved following JQ1 treatment. Studies have shown that these transcription factors play a beneficial role in many pathophysiological processes. Overexpression of Atf, for example, can alleviate ischemia-reperfusion injury in the heart by reducing oxidative stress [78]. Indeed, Atf3 may be a target of Nrf2 and may therefore be involved in the regulation of oxidative stress [78]. JunD, a member of the AP-1 transcription factor family, plays a protective role in diabetic cardiomyopathy through the regulation of antioxidative stress [79]. Similarly, Cebpd has been shown to be involved in inhibiting oxidative stress and maintaining mitochondrial function [80, 81]. Here, we predicted the transcription factors of angiogenesis-promoting genes including Gpx3, Gstm1, and Gstt1. Among the predicted transcription factors, Egr1, which was also enriched in branch 2, was of particular interest. Multiple studies have reported that Egr1 promotes collagen synthesis and fibrosis [82]. Egr1 has also been shown to lead to upregulation of oxidative stress levels and has been associated with a variety of adverse outcomes, such as myocardial fibrosis, renal fibrosis, pulmonary hypertension, and arrhythmia after myocardial infarction [83–86]. However, in a model of myocardial ischemia-reperfusion injury, remote ischemic preconditioning was found to improve myocardial ischemia-reperfusion injury, through the protective role of Egr1 against apoptosis via the Jak-Stat pathway [87]. In most studies, Egr1 has been examined in the context of an acute pathological model. However, in the cardiac stress overload model, Egr1 was also studied in the context of myocardial hypertrophy. To date, there are no reports describing the expression and function of Egr1 in CFs in a chronic TAC model. However, Cupesi et al. reported that in a TAC model, Egr1 was upregulated after week 1, but downregulated after week 3 [88].

Based on our scRNA-seq analysis of the TAC model, we found that Egr1 expression levels were downregulated in fibroblasts in the TAC model. However, JQ1 treatment led to upregulation of Egr1 expression levels, which was accompanied by improved fibrosis. Thus, we propose that Egr1 expressed by fibroblasts may play a protective role in the model of chronic cardiac pressure overload. Our results show that the function of Egr1 may be inconsistent with most literature reports, which is worthy of further exploration. Finally, this study was carried out based on the analysis of single-cell sequencing data and has not been verified by experiments, which is the deficiency of this study.

5. Conclusions

This study found that there were two distinct cell fates in CFs. One fate may be related to angiogenesis and antioxidative stress, accompanied by metabolic reprogramming. Furthermore, Gpx3 and Egr1 may be involved in promoting the differentiation of CFs into a protective state.

Data Availability

The dataset of the transverse aortic coarctation (TAC) model in mice was downloaded from the GSE155882 dataset.

Additional Points

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Guoxing Li and Yuhong Qin contributed equally and co-first authors.

Acknowledgments

Heartfelt thanks are due to Michael Alexanian and his team for selflessly sharing their valuable data, which has furthered our understanding of myocardial fibrosis.

Supplementary Materials

Supplementary Figure 1: (a) the vlnplot shows the nFeatures and percent mt of all cell subsets. (b) Unsupervised clustering of all cells visualized by groups, which showed that there was no obvious batch effect. (c) FeaturePlot showed the markers of fibroblast. Supplementary Figure 2: (a) the expression of Gpx3, Gstm1, Ggt5, Gsta3, Gstt1, and Gstt1 in three branches of the trajectory. (b) Comparative analysis of expression patterns of Gpx3, Colla1, and Postn. Supplementary Figure 3: (a) heat map of genes related to glycogen synthesis, glycogen decomposition, and pentose phosphate pathway. (b) We renamed the fibroblasts with branch labels and then selected subgroups for reclustering before performing receptor ligand interaction analysis. Supplementary Table 1: top 20 markers of all subsets. Supplementary Table 2: GSEA results of KEGG and GO. Supplementary Table 3: list of fibrogenic genes. Supplementary Table 4: GO analysis of three branches. Supplementary Table 5: list of gene encoding secreted protein. Supplementary Table 6: list of angiogenesis genes. (Supplementary Materials)
References

[1] P. Alam, B. D. Maliken, S. M. Jones et al., "Cardiac remodeling and repair: recent approaches, advancements, and future perspective," *International Journal of Molecular Sciences*, vol. 22, no. 23, p. 13104, 2021.

[2] C. C. Nwabuo and R. S. Vasan, "Pathophysiology of hypertensive heart disease: beyond left ventricular hypertrophy," *Current Hypertension Reports*, vol. 22, no. 2, p. 11, 2020.

[3] Z. Varasteh, W. A. Weber, and C. Rischpler, "Nuclear molecular imaging of cardiac remodeling after myocardial infarction," *Pharmaceuticals*, vol. 15, no. 2, p. 183, 2022.

[4] P. Debonnaire, V. Delgado, and J. J. Bax, "Potential role of fibrosis imaging in severe valvular heart disease," *Heart*, vol. 101, no. 5, pp. 397–407, 2015.

[5] J. G. Travers, F. A. Kamal, J. Robbins, K. E. Yutzey, and B. C. Blaxall, "Cardiac fibrosis: the fibroblast awakens," *Circulation Research*, vol. 118, no. 6, pp. 1021–1040, 2016.

[6] R. Weiskirchen, S. Weiskirchen, and F. Tacke, "Organ and tissue fibrosis: molecular signals, cellular mechanisms and translational implications," *Molecular Aspects of Medicine*, vol. 65, pp. 2–15, 2019.

[7] K. Sun, Y. Y. Li, and J. Jin, "A double-edged sword of immunomicroenvironment in cardiac homeostasis and injury repair," *Signal Transduction and Targeted Therapy*, vol. 6, no. 1, p. 79, 2021.

[8] B. Widyantoro, N. Emoto, K. Nakayama et al., "Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition," *Circulation*, vol. 121, no. 22, pp. 2407–2418, 2010.

[9] S. D. Prabhu and N. G. Frangogiannis, "The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis," *Circulation Research*, vol. 119, no. 1, pp. 91–112, 2016.

[10] L. U. Pagan, M. J. Gomes, M. Gatto, G. A. F. Mota, K. Okoshi, and M. P. Okoshi, "The role of oxidative stress in the aging heart," *Antioxidants*, vol. 11, no. 2, p. 336, 2022.

[11] A. A. Gibb, M. P. Lazaropoulos, and J. W. Elrod, "Myofibroblasts and fibrosis: mitochondrial and metabolic control of cellular differentiation," *Circulation Research*, vol. 127, no. 3, pp. 427–447, 2020.

[12] W. Qin, L. Cao, and I. Y. Massey, "Role of PI3K/Akt signaling pathway in cardiac fibrosis," *Molecular and Cellular Biochemistry*, vol. 476, no. 11, pp. 4045–4059, 2021.

[13] B. López, S. Ravassa, M. U. Moreno et al., "Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches," *Nature Reviews Cardiology*, vol. 18, no. 7, pp. 479–498, 2021.

[14] A. C. Adey, "Augmentation-based single-cell genomics," *Genome Research*, vol. 31, no. 10, pp. 1693–1705, 2021.

[15] M. Litvinukova, C. Talavera-López, H. Maatz et al., "Cells of the adult human heart," *Nature*, vol. 588, no. 7838, pp. 466–472, 2020.

[16] A. Ruiz-Villalba, J. P. Romero, S. C. Hernández et al., "Single-cell RNA sequencing analysis reveals a crucial role for CTHRC1 (collagen triple helix repeat containing 1) cardiac fibroblasts after myocardial infarction," *Circulation*, vol. 142, no. 19, pp. 1831–1847, 2020.

[17] M. Alexanian, P. F. Prztycki, R. Micheletti et al., "A transcriptional switch governs fibroblast activation in heart disease," *Nature*, vol. 595, no. 7867, pp. 438–443, 2021.

[18] L. Zhuang, L. Lu, R. Zhang, K. Chen, and X. Yan, "Comprehensive integration of single-cell transcriptional profiling reveals the heterogeneities of non-cardiomyocytes in healthy and ischemic hearts," *Frontiers in Cardiovascular Medicine*, vol. 7, p. 615161, 2020.

[19] C. S. McGinnis, L. M. Murrow, and Z. J. Gartner, "DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors," *Cell Systems*, vol. 8, no. 4, pp. 329–337.e4, 2019.

[20] R. Satija, J. A. Farrell, D. Gennert, A. F. Schier, and A. Regev, "Spatial reconstruction of single-cell gene expression data," *Nature Biotechnology*, vol. 33, no. 5, pp. 495–502, 2015.

[21] I. Korsunsky, N. Millard, J. Fan et al., "Fast, sensitive and accurate integration of single-cell data with harmony," *Nature Methods*, vol. 16, no. 12, pp. 1289–1296, 2019.

[22] X. Qiu, Q. Mao, Y. Tang et al., "Reversed graph embedding resolves complex single-cell trajectories," *Nature Methods*, vol. 14, no. 10, pp. 979–982, 2017.

[23] G. Yu, L. G. Wang, Y. Han, and Q. Y. He, "clusterProfiler: an R package for comparing biological themes among gene clusters," *OMICS*, vol. 16, no. 5, pp. 284–287, 2012.

[24] P. Shannon, A. Markiel, O. Ozier et al., "Cytoscape: a software environment for integrated models of biomolecular interaction networks," *Genome Research*, vol. 13, no. 11, pp. 2498–2504, 2003.

[25] C. H. Holland, J. Tanevski, J. Perales-Patón et al., "Robustness and applicability of transcription factor and pathway analysis tools on single-cell RNA-seq data," *Genome Biology*, vol. 21, no. 1, p. 36, 2020.

[26] A. B. Keenan, D. Torre, A. Lachmann et al., "ChEA3: transcription factor enrichment analysis by orthogonal omics integration," *Nucleic Acids Research*, vol. 47, no. W1, pp. W212–W224, 2019.

[27] R. Browaeys, W. Saelens, and Y. Saeyts, "NicheNet: modeling intercellular communication by linking ligands to target genes," *Nature Methods*, vol. 17, no. 2, pp. 159–162, 2020.

[28] P. Filippakopoulos, J. Qi, S. Picaud et al., "Selective inhibition of BET bromodomains," *Nature*, vol. 468, no. 7327, pp. 1067–1073, 2010.

[29] T. Oka, J. Xu, R. A. Kaiser et al., "Genetic manipulation of peroxisome expression reveals a role in cardiac hypertrophy and ventricular remodeling," *Circulation Research*, vol. 101, no. 3, pp. 313–321, 2007.

[30] W. Ding, W. Pu, S. Jiang et al., "Evaluation of the antifibrotic potency by knocking down SPARC, CCR2 and SMAD3," *eBioMedicine*, vol. 38, pp. 238–247, 2018.

[31] Q. J. Zhang, Y. He, Y. Li et al., "Matricellular protein Cilp1 promotes myocardial fibrosis in response to myocardial infarction," *Circulation Research*, vol. 129, no. 11, pp. 1021–1035, 2021.

[32] A. R. Pinto, A. Ilinykh, M. J. Ivey et al., "Revisiting cardiac cellular composition," *Circulation Research*, vol. 118, no. 3, pp. 400–409, 2016.

[33] M. Deng, S. Yang, Y. Ji et al., "Overexpression of peptidase inhibitor 16 attenuates angiotensin II–induced cardiac fibrosis via regulating HDAC1 of cardiac fibroblasts," *Journal of Cellular and Molecular Medicine*, vol. 24, no. 9, pp. 5249–5259, 2020.

[34] Y. Wang, Y. Hou, W. Zhang et al., "Lipolytic inhibitor G052 modulates glioma stem-like cell radiation response," *Journal of Experimental & Clinical Cancer Research*, vol. 38, no. 1, p. 147, 2019.
H. Y. Liu, L. F. Yu, T. G. Zhou et al., “Promoter hypermethylation and suppression of glutathione peroxidase 3 are associated with inflammatory breast carcinogenesis,” *Oxidative Medicine and Cellular Longevity*, vol. 2014, Article ID 787195, 9 pages, 2014.

T. Shimosawa, Y. Shibagaki, K. Ishibashi et al., “Adrenomedul- lin, an endogenous peptide, counteracts cardiovascular damage,” *Circulation*, vol. 105, no. 1, pp. 106–111, 2002.

J. Pires Da Silva, K. Monceaux, A. Guilbert et al., “SIRT1 protects the heart from ER stress-induced injury by promoting eEF2K/eEF2-dependent autophagy,” *Cell*, vol. 9, no. 2, p. 426, 2020.

Q. Jin, R. Li, N. Hu et al., “DUSP1 alleviates cardiac ischemia/reperfusion injury by suppressing the Mff- required mitochondrial fission and Bnip3-related mitophagy via the JNK pathways,” *Redox Biology*, vol. 14, pp. 576–587, 2018.

J. K. Jin, E. A. Blackwood, K. Azizi et al., “ATF6 decreases myocardial ischemia/reperfusion damage and links ER stress and oxidative stress signaling pathways in the heart,” *Circulation Research*, vol. 120, no. 5, pp. 862–875, 2017.

U. Raaz, I. N. Schellinger, E. Chernogubova et al., “Transcription factor Runx2 promotes aortic fibrosis and stiffness in type 2 diabetes mellitus,” *Circulation Research*, vol. 117, no. 6, pp. 513–524, 2015.

G. Lewin, M. Matus, A. Basu et al., “Critical role of transcription factor cyclic AMP response element modulator in beta1-adrenoceptor-mediated cardiac dysfunction,” *Circulation*, vol. 119, no. 1, pp. 79–88, 2009.

D. Bugg, R. Bretherton, P. Kim et al., “Infarct collagen topology regulates fibroblast fate via p38-yes-associated protein transcriptional enhanced associate domain signals,” *Circulation Research*, vol. 127, no. 10, pp. 1306–1322, 2020.

N. M. Khan, I. Ahmad, and T. M. Haqqui, “Nrf2/ARE pathway attenuates oxidative and apoptotic response in human osteoarthritis chondrocytes by activating ERK1/2/ELK1-P70S6K-P90RSK signaling axis,” *Free Radical Biology & Medicine*, vol. 116, pp. 159–171, 2018.

S. Menaizza, J. Sun, S. Appachi et al., “Non-nuclear estrogen receptor alpha activation in endothelium reduces cardiac ischemia-reperfusion injury in mice,” *Journal of Molecular and Cellular Cardiology*, vol. 107, pp. 41–51, 2017.

H. Y. Liu, L. F. Yu, T. G. Zhou et al., “Lipopolysaccharide-stimulated bone marrow mesenchymal stem cells-derived exosomes inhibit H2O2-induced cardiomyocyte inflammation and oxidative stress via regulating miR-181a-5p/ATF2 axis,” *European Review for Medical and Pharmacological Sciences*, vol. 24, no. 19, pp. 10069–10077, 2020.

C. Janani and B. D. Ranjitha Kumari, “PPAR gamma gene—a review,” *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, vol. 9, no. 1, pp. 46–50, 2015.

F. U. Hassan, A. Nadeem, Z. Li et al., “Role of peroxisome proliferator-activated receptors (PPARs) in energy homeostasis of dairy animals: exploiting their modulation through nutrigenomic interventions,” *International Journal of Molecular Sciences*, vol. 22, no. 22, p. 12463, 2021.

S. Azhar, “Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease,” *Future Cardiology*, vol. 6, no. 5, pp. 657–691, 2010.

Q. Lu, S. Hu, P. Guo et al., “PPAR-y with its anti-fibrotic action could serve as an effective therapeutic target in T-2 toxin-induced cardiac fibrosis of rats,” *Food and Chemical Toxicology*, vol. 152, p. 112183, 2021.

W. Lei, X. Li, L. Li et al., “Compound Danshen dripping pill ameliorates post ischemic myocardial inflammation through synergistically regulating MAPK, PI3K/AKT and PPAR signaling pathways,” *Journal of Ethnopharmacology*, vol. 281, p. 114438, 2021.

K. D. Wagner and N. Wagner, “PPARs and myocardial infarction,” *International Journal of Molecular Sciences*, vol. 21, no. 24, p. 9436, 2020.

B. Chen, S. Huang, Y. Su et al., “Macrophage Smad3 protects the infarcted heart, stimulating phagocytosis and regulating inflammation,” *Circulation Research*, vol. 125, no. 1, pp. 55–70, 2019.

S. Garg, S. I. Khan, R. K. Malhotra et al., “The molecular mechanism involved in cardioprotection by the dietary flavonoid fisetin as an agonist of PPAR-y in a murine model of myocardial infarction,” *Archives of Biochemistry and Biophysics*, vol. 694, p. 108572, 2020.

Q. Lu, P. Guo, J. Guo et al., “Targeting peroxisome proliferator-activated receptors: a new strategy for the treatment of cardiac fibrosis,” *Pharmacology & Therapeutics*, vol. 219, p. 107702, 2021.

X. N. Xie, Z. Tan, S. Banerjee et al., “Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis,” *American Journal of Respiratory and Critical Care Medicine*, vol. 192, no. 12, pp. 1462–1474, 2015.

M. Barcena-Varela, H. Paish, L. Alvarez et al., “Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis,” *Gut*, vol. 70, no. 2, pp. 388–400, 2021.

Q. Li, C. Li, A. Elnowasany et al., “PKM1 exerts critical roles in cardiac remodeling under pressure overload in the heart,” *Circulation*, vol. 144, no. 9, pp. 712–727, 2021.

Z. T. Chen, Q. Y. Gao, M. X. Wu et al., “Glycolysis inhibition alleviates cardiac fibrosis after myocardial infarction by suppressing cardiac fibroblast activation,” *Frontiers in Cardiovascular Medicine*, vol. 8, p. 701745, 2021.

M. Jiang, X. Xie, F. Cao, and Y. Wang, “Mitochondrial metabolism in myocardial remodeling and mechanical unloading: implications for ischemic heart disease,” *Frontiers in Cardiovascular Medicine*, vol. 8, p. 79267, 2021.

T. C. Cheng, J. L. Philip, D. M. Tabima, T. A. Hacker, and N. C. Chesler, “Multiscale structure-function relationships in right ventricular failure due to pressure overload,” *American Journal of Physiology. Heart and Circulatory Physiology*, vol. 315, no. 3, pp. H699–H708, 2018.

X. Han, C. Ding, X. N. Sang et al., “Targeting Sirtuin1 to treat aging-related tissue fibrosis: from prevention to therapy,” *Pharmacology & Therapeutics*, vol. 229, p. 107983, 2022.

R. Yao, Y. Cao, C. Wang et al., “Taohuajing reduces oxidative stress and inflammation in diabetic cardiomyopathy through the sirtuin 1/nucleotide-binding oligomerization domain-like receptor protein 3 pathway,” *BMC Complementary Medicine and Therapies*, vol. 21, no. 1, p. 78, 2021.

Y. Purnomo, Y. Piccart, T. Coenen, J. Prihadi, and P. Lijnen, “Oxidative stress and transforming growth factor-β1-induced cardiac fibrosis,” *Cardiovascular & Hematological Disorders Drug Targets*, vol. 13, no. 2, pp. 165–172, 2013.

H. Liu, L. Wang, X. Weng et al., “Inhibition of Brd4 alleviates renal ischemia/reperfusion injury-induced apoptosis
and endoplasmic reticulum stress by blocking FoxO4-mediated oxidative stress,” *Redox Biology*, vol. 24, p. 101195, 2019.

[65] E. L. Mills, B. Kelly, A. Logan et al., “Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages,” *Cell*, vol. 167, no. 2, pp. 457–470.e13, 2016.

[66] H. A. Prag, L. Pala, D. Kula-Alwar et al., “Ester prodrugs of malonate with enhanced intracellular delivery protect against cardiac ischemia-reperfusion injury in vivo,” *Cardiovascular Drugs and Therapy*, vol. 36, no. 1, pp. 1–13, 2022.

[67] A. Tin, R. Scharpf, M. M. Estrella et al., “The loss of GSTM1 associates with kidney failure and heart failure,” *Journal of the American Society of Nephrology*, vol. 28, no. 11, pp. 3345–3352, 2017.

[68] Y. Song, Z. Shan, X. Liu et al., “An updated meta-analysis showed smoking modify the association of GSTM1null genotype on the risk of coronary heart disease,” *Bioscience Reports*, vol. 41, no. 2, 2021.

[69] M. Cresci, I. Fossa, L. Ait-Ali et al., “Maternal and paternal environmental risk factors, metabolizing GSTM1 and GSTT1 polymorphisms, and congenital heart disease,” *The American Journal of Cardiology*, vol. 108, no. 11, pp. 1625–1631, 2011.

[70] E. Olson, M. Pravenec, V. Landa et al., “Transgenic overexpression of glutathione S-transferase μ-type 1 reduces hypertension and oxidative stress in the stroke-prone spontaneously hypertensive rat,” *Journal of Hypertension*, vol. 37, no. 5, pp. 985–996, 2019.

[71] J. Lu, Q. H. Liu, F. Wang et al., “Exosomal miR-9 inhibits angiogenesis by targeting MKD and regulating PDK/AKT pathway in nasopharyngeal carcinoma,” *Journal of Experimental & Clinical Cancer Research*, vol. 37, no. 1, p. 147, 2018.

[72] C. Balser, A. Wolf, M. Herb, and T. Langmann, “Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina,” *Journal of Neuroinflammation*, vol. 16, no. 1, p. 26, 2019.

[73] C. H. Lai, A. T. Chen, A. B. Burns et al., “RAMP2-AS1 regulates endothelial homeostasis and aging,” *Frontiers in Cell and Development Biology*, vol. 9, p. 633507, 2021.

[74] H. Xu, K. Pumiglia, and S. E. LaFlamme, “Laminin-511 and α6 integrins regulate the expression of CXCR4 to promote endothelial morphogenesis,” *Journal of Cell Science*, vol. 133, no. 11, 2020.

[75] A. Babinska, C. C. Clement, T. Przygrodzki et al., “A peptide antagonist of F11R/JAM-A reduces plaque formation and prolongs survival in an animal model of atherosclerosis,” *Atherosclerosis*, vol. 284, pp. 92–101, 2019.

[76] A. J. Mouton, Y. Ma, O. J. Rivera Gonzalez et al., “Fibroblast polarization over the myocardial infarction time continuum shifts roles from inflammation to angiogenesis,” *Basic Research in Cardiology*, vol. 114, no. 2, p. 6, 2019.

[77] D. Unterleuthner, P. Neuhold, K. Schwarz et al., “Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer,” *Angiogenesis*, vol. 23, no. 2, pp. 159–177, 2020.

[78] Y. Liu, Y. Hu, J. Xiong, and X. Zeng, “Overexpression of activating transcription factor 3 alleviates cardiac microvascular ischemia/reperfusion injury in rats,” *Frontiers in Pharmacology*, vol. 12, p. 598959, 2021.

[79] S. Hussain, A. W. Khan, A. Akhmedov et al., “Hyperglycemia induces myocardial dysfunction via epigenetic regulation of JunD,” *Circulation Research*, vol. 127, no. 10, pp. 1261–1273, 2020.

[80] S. Banerjee, N. Aykin-Burns, K. J. Krager et al., “Loss of C/EBPδ enhances IR-induced cell death by promoting oxidative stress and mitochondrial dysfunction,” *Free Radical Biology & Medicine*, vol. 99, pp. 296–307, 2016.

[81] S. Banerjee, T. Alexander, D. Majumdar et al., “Loss of C/EBPδ exacerbates radiation-induced cognitive decline in aged mice due to impaired oxidative stress response,” *International Journal of Molecular Sciences*, vol. 20, no. 4, p. 885, 2019.

[82] J. Li, L. Gong, R. Zhang et al., “Fibroblast growth factor 21 inhibited inflammation and fibrosis after myocardial infarction via EGR1,” *European Journal of Pharmacology*, vol. 910, p. 174470, 2021.

[83] J. Li, C. Xu, Y. Liu et al., “Fibroblast growth factor 21 inhibited ischemic arrhythmias via targeting miR-143/EGRI axis,” *Basic Research in Cardiology*, vol. 115, no. 2, p. 9, 2020.

[84] K. Ai, X. Li, P. Zhang et al., “Genetic or siRNA inhibition of MBD2 attenuates the UUO- and I/R-induced renal fibrosis via downregulation of EGR1,” *Molecular Therapy–Nucleic Acids*, vol. 28, pp. 77–86, 2022.

[85] D. E. van der Feen, M. G. Dickinson, B. Bartelds et al., “Egr-1 identifies neointimal remodeling and relates to progression in human pulmonary arterial hypertension,” *The Journal of Heart and Lung Transplantation*, vol. 35, no. 4, pp. 481–490, 2016.

[86] F. Z. Marques, E. Nelson, P. Y. Chu et al., “High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice,” *Circulation*, vol. 135, no. 10, pp. 964–977, 2017.

[87] S. Zhang, X. Tao, Q. Cao et al., “Innate immune cell response to pressure overload in a lamin A/C haploinsufficient mouse,” *European Journal of Pharmacology*, vol. 20, no. 4, p. 885, 2019.

[88] J. Ai, X. Li, P. Zhang et al., “Genetic or siRNA inhibition of MBD2 attenuates the UUO- and I/R-induced renal fibrosis via downregulation of EGR1,” *Molecular Therapy–Nucleic Acids*, vol. 28, pp. 77–86, 2022.

[89] D. E. van der Feen, M. G. Dickinson, B. Bartelds et al., “Egr-1 identifies neointimal remodeling and relates to progression in human pulmonary arterial hypertension,” *The Journal of Heart and Lung Transplantation*, vol. 35, no. 4, pp. 481–490, 2016.

[90] F. Z. Marques, E. Nelson, P. Y. Chu et al., “High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice,” *Circulation*, vol. 135, no. 10, pp. 964–977, 2017.

[91] S. Zhang, X. Tao, Q. Cao et al., “Innate immune cell response to pressure overload in a lamin A/C haploinsufficient mouse,” *European Journal of Pharmacology*, vol. 20, no. 4, p. 885, 2019.